Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis

Clinical and Experimental Immunology

Volumn 165, Issue 1, 2011, Pages 121-129

  Jochems, C ^a   Islander, U ^a   Erlandsson, M ^a   Engdahl, C ^a   Lagerquist, M ^a   Ohlsson, C ^a   Nandakumar, K S ^b,c   Holmdahl, R ^b,c   Carlsten, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BMD; CAIA; CIA; Luciferase ERE; Oestradiol; Ovariectomy; Raloxifene

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; ESTRADIOL BENZOATE; INTERLEUKIN 6; LUCIFERASE; OSTEOCALCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BIOASSAY; BONE DENSITY; BONE MARROW; BONE TURNOVER; CARTILAGE TURNOVER; COLLAGEN ANTIBODY INDUCED ARTHRITIS; COLLAGEN INDUCED ARTHRITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; MALE; MENOPAUSE RELATED DISORDER; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSAL ARTHRITIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SECONDARY OSTEOPOROSIS; SPLEEN;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; BONE MARROW; COLLAGEN; DISEASE PROGRESSION; ESTRADIOL; FEMALE; HUMANS; IMMUNOMODULATION; MICE; MICE, INBRED DBA; MICE, TRANSGENIC; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RALOXIFENE; RESPONSE ELEMENTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRANSGENES;

EID: 79958170434     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04397.x     Document Type: Article

References (43)

1. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46:625-31.
2. Forsblad D'Elia H, Larsen A, Waltbrand E etal. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003; 62:617-23.
3. Sinigaglia L, Nervetti A, Mela Q etal. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000; 27:2582-9.
4. Forsblad D'Elia H, Larsen A, Mattsson LA etal. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003; 30:1456-63.
5. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005; 118:64-73.
6. Jochems C, Islander U, Kallkopf A, Lagerquist M, Ohlsson C, Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum 2007; 56:3261-70.
7. Jochems C, Lagerquist M, Hakansson C, Ohlsson C, Carlsten H. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 2008; 152:593-7.
8. Latham KA, Zamora A, Drought H etal. Estradiol treatment redirects the isotype of the autoantibody response and prevents the development of autoimmune arthritis. J Immunol 2003; 171:5820-7.
9. Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005; 7:R837-43.
10. Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods 2005; 304:126-36.
11. Burkhardt H, Koller T, Engstrom A etal. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 2002; 46:2339-48.
12. Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003; 163:1827-37.
13. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT, van der Burg B. Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 2004; 32:689-701.
14. van Vollenhoven RF, Houbiers JG, Buttgereit F etal. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. Arthritis Rheum 2010; 62:3832-3.
15. Roman-Blas JA, Castaneda S, Cutolo M, Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor-beta agonist, ERB-041, in patients with rheumatoid arthritis. Arthritis Care Res 2010; 62:1588-93.
16. Dulos J, Vijn P, van Doorn C etal. Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor alpha but not estrogen receptor beta. Arthritis Res Ther 2010; 12:R101.
17. Harris HA, Albert LM, Leathurby Y etal. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003; 144:4241-9.
18. Engdahl C, Jochems C, Windahl SH etal. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis Rheum 2010; 62:524-33.
19. Erlandsson MC, Gomori E, Taube M, Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 2000; 205:103-9.
20. Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002; 175:319-27.
21. Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 2000; 15:541-9.
22. Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog L. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986; 29:106-13.
23. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 1999; 104:895-901.
24. Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A. Genistein as an anti-inflammatory agent. Inflamm Res 2003; 52:341-6.
25. Bremell T, Abdelnour A, Tarkowski A. Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect Immun 1992; 60:2976-85.
26. Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988; 18:1535-40.
27. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992; 31:583-91.
28. Mansson B, Carey D, Alini M etal. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95:1071-7.
29. Joosten LA, Lubberts E, Helsen MM etal. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999; 1:81-91.
30. Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986; 29:1501-9.
31. Jansson L, Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV: progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 1989; 15:141-50.
32. Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001; 28:634-40.
33. Jansson L, Mattsson A, Mattsson R, Holmdahl R. Estrogen induced suppression of collagen arthritis. V: physiological level of estrogen in DBA/1 mice is therapeutic on established arthritis, suppresses anti-type II collagen T-cell dependent immunity and stimulates polyclonal B-cell activity. J Autoimmun 1990; 3:257-70.
34. Nuttall ME, Fisher PW, Suva LJ, Gowen M. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro. Eur J Cancer 2000; 36 (Suppl. 4):S63-4.
35. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273:1222-5.
36. Paech K, Webb P, Kuiper GG etal. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277:1508-10.
37. Weisz A, Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 1990; 18:5097-106.
38. Blanque R, Cottereaux C, Gardner CR. Increases in osteocalcin after ovariectomy are amplified by LPS injection: strain differences in bone remodelling. Gen Pharmacol 1998; 30:51-6.
39. Gao Y, Grassi F, Ryan MR etal. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117:122-32.
40. Amirahmadi SF, Pho MH, Gray RE etal. An arthritogenic monoclonal antibody to type II collagen, CII-C1, impairs cartilage formation by cultured chondrocytes. Immunol Cell Biol 2004; 82:427-34.
41. Crombie DE, Turer M, Zuasti BB etal. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res Ther 2005; 7:R927-37.
42. Amirahmadi SF, Whittingham S, Crombie DE etal. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. Arthritis Rheum 2005; 52:1897-906.
43. Nandakumar KS, Bajtner E, Hill L etal. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008; 58:184-96.